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AbsTrACT
Aims In addition to providing external quality 
assessment (EQA) schemes, United Kingdom National 
External Quality Assessment service (UK NEQAS) for 
Molecular Genetics also supports the education of 
laboratories. As an enhancement to the Molecular 
Pathology EQA scheme, a human cell-line reference 
sample, manufactured by Thermo Fisher Scientific 
(AcroMetrix), was provided for analysis. This contained 
many variants, present at frequencies between 1% and 
17.9%.
Methods One hundred and one laboratories submitted 
results, with a total of 2889 test results on 53 genes 
being reported. Known polymorphisms, 46/2889 (1.59%) 
results, were excluded. Variants detected in the seven 
most commonly reported (and clinically relevant) genes, 
KRAS, NRAS, BRAF, EGFR, PIK3CA, KIT and PDGFRA, are 
reported here, as these genes fall within the scope of UK 
NEQAS EQA schemes.
results Next generation sequencing (NGS) was the 
most commonly performed testing platform. There were 
between 5 and 27 validated variants in the seven genes 
reported here. Eight laboratories correctly reported all 
five NRAS variants, and two correctly reported all eight 
BRAF variants. The validated mean variant frequency was 
lower than that determined by participating laboratories, 
with single-gene testing methodologies showing less 
variation in estimated frequencies than NGS platforms. 
Laboratories were more likely to correctly identify 
clinically relevant variants.
Conclusions Over 100 laboratories took the 
opportunity to test the ’educational reference sample’, 
showing a willingness to further validate their testing 
platforms. While it was encouraging to see that the most 
widely reported variants were those which should be 
included in routine testing panels, reporting of variants 
was potentially open to interpretation, thus clarity is still 
required on whether laboratories selectively reported 
variants, by either clinical relevance or variant frequency.
InTrOduCTIOn
Having moved well into the era of personalised 
medicine, laboratories are being called on to 
routinely test solid tumours, such a colorectal,1–5 
lung,6–9 melanoma10 and gastrointestinal stromal 
tumours (GIST)11–13 for a variety of biomarkers, 
which will determine treatment options.
One way to monitor accuracy and reproduc-
ibility of testing is through participation in external 
quality assessment (EQA) schemes. Several studies 
have demonstrated the benefits of scheme partic-
ipation,14–18 having seen an improvement that is, 
a decrease in genotyping errors, with continuous 
EQA participation.
The United Kingdom National External Quality 
Assessment service (UK NEQAS) for Molecular 
Genetics has been providing EQA schemes for the 
assessment of colorectal cancer (CRC) (since 2009), 
lung cancer (since 2010), melanoma (since 2012) 
and GIST (since 2008). The scheme sends tumour 
samples to participating laboratories 2–3 times per 
year and provides an assessment of genotyping, 
interpretation and clerical accuracy. These molec-
ular pathology EQAs are ISO 17043 (https://www. 
iso. org/ standard/ 29366. html) accredited.
In addition to the samples sent out as part of 
run 2 of the 2015–16 Molecular Pathology EQA 
schemes, a manufactured human cell-line reference 
sample (Thermo Fisher Scientific (AcroMetrix)) 
was also distributed to laboratories. Here we report 
on the data gathered from 101 laboratories, who 
returned genotyping and variant allele frequency 
results.
MATerIAls And MeThOds
UK NEQAS for Molecular Genetics supplied an 
educational EQA case using a reference sample as 
part of the Molecular Pathology 2015–2016 run 
2 distributions. One rolled section (10 µm thick-
ness) of formalin-fixed paraffin-embedded (FFPE) 
cell-line material was provided to each laboratory. 
This was manufactured by Thermo Fisher Scientific 
(AcroMetrix), to contain a large number of vari-
ants, present at varying frequencies. These frequen-
cies were independently validated by digital droplet 
PCR prior to distribution.
Laboratories participating in the CRC, lung 
cancer, melanoma and GIST Molecular Pathology 
EQA schemes were invited, as a voluntary exercise, 
to extract DNA from the FFPE section and test 
using their routine protocols for any of the targets 
in table 1.
Results were submitted using a supplied 
proforma, which also requested information on test 
methodology and the percentage variant frequency 
detected for each variant reported.
No EQA scores were assigned to participating 
laboratories, and the Scheme subsequently 
provided these laboratories with a complete 
breakdown of the validated variant frequencies 
within each gene, thus allowing the reassessment 
of raw data, if variants had not been identified by 
participants.
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Table 1 Genes which could be tested for the presence of variants in 
the reference sample
ABL1 EGFR GNA11 KIT PDGFRA VHL 
AKT1 ERBB2 GNAQ KRAS PIK3CA TP53
ALK ERBB4 GNAS MAP2K1 PTEN
APC EZH2 HNF1A MET PTPN11
ATM FBXW7 HRAS MLH1 RB1
BRAF FGFR1 IDH1 MPL RET
CDH1 FGFR2 IDH2 MSH6 SMAD4
CDKN2A FGFR3 JAK2 NOTCH1 SMARCB1
CSF1R FLT3 JAK3 NPM1 SMO
CTNNB1 FOXL2 KDR NRAS STK11
Figure 1 Genes tested by participating laboratories.
Table 2 Percentage of all results submitted which were obtained by 
NGS
Gene
number of results 
reported by nGs
Percentage of the total number of 
results reported by nGs (%)
BRAF 115 56.1
EGFR 298 81.4
KIT 143 59.1
KRAS 115 56.1
NRAS 128 59
PDGFRA 84 92.3
PIK3CA 230 94.3
NGS, next generation sequencing.
resulTs
Participation
One hundred and one laboratories tested this reference sample 
and submitted results. Several laboratories carried out more than 
one test methodology and therefore reported multiple results. 
A total of 2889 test results were reported spanning 53 different 
genes. There were only 52 different genes in the reference 
sample; however, one laboratory unexpectedly reported test 
results for proto-oncogene tyrosine-protein kinase Src (SRC). 
Known polymorphisms, which accounted for 1.59% of results, 
were excluded from subsequent analysis. Fifty-eight variants 
present in the reference sample were incorrectly reported as ‘no 
mutation detected’, spread over 17 different genes. The analysis 
reported here is confined to the seven most commonly tested 
genes: KRAS, NRAS, BRAF, EGFR, PIK3CA, KIT and PDGFRA 
(figure 1).
Testing methodologies
The most commonly used mutation test was by next gener-
ation sequencing (NGS), with 48/101 (47.5%) of laboratories 
returning data using NGS. The percentage of results reported by 
NGS, compared with single-gene technologies (pyrosequencing, 
Sanger sequencing, mass spectrometry, real-time PCR, Stri-
pAssay, EntroGen mutation kits, Cobas 4800, LightMix Kit) is 
shown in table 2. The Ion Torrent was the preferred NGS plat-
form for the testing of all genes, with the Illumina platform being 
the second most common. Data provided by participants relating 
to the panel used were sparse, but most commonly reported was 
the AmpliSeq for Illumina Cancer Hotspot Panel V.2.
Variants and variant allele frequencies
The number of validated variants within each of the seven most 
commonly tested genes is shown in table 3, along with the mean 
validated frequency. Digital droplet PCR was used by Thermo 
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Table 3 Validated variant numbers and frequencies within the seven 
most commonly reported genes
Gene number of variants present Mean variant frequency (%)
BRAF 8 2.6
EGFR 27 2.6
KIT 24 4.2
KRAS 8 4.3
NRAS 5 7.4
PDGFRA 8 4.2
PIK3CA 24 4.7
Table 4 The number of laboratories incorrectly reporting a WT result
Gene
Mean 
variant 
frequency 
(%)
number of 
laboratories 
reporting WT 
result
number of tests 
performed with 
no variants 
reported
Methodologies 
employed (n)
BRAF 2.6 21 22 Sanger (4),
Pyrosequencing (4),
Cobas 4800 (5),
RT-PCR (2),
HRM (2)*
EGFR 2.6 3 6 Sanger (1), 
Pyrosequencing (1),
NGS/Ion Torrent (2), 
RT-PCR (1)
KIT 4.2 1 1 Sanger (1)
KRAS 4.3 7 9 Sanger (4), 
Pyrosequencing (2), 
NGS/Ion Torrent (1), 
RT-PCR (1),
Entrogen (1)
NRAS 7.4 3 5 Sanger† (2), 
Pyrosequencing (2),
NGS/Ion Torrent (1)
PDGFRA 4.2 1 1 Sanger (1)
PIK3CA 4.7 1 2 Pyrosequencing (1),
NGS/Ion Torrent (1)
*In addition to those listed in the table, one laboratory used Therascreen, one 
laboratory used Amoy Dx BRAF Mutation Detection kit, one laboratory used Idylla, 
one laboratory performed NGS on an Ion Torrent platform and one laboratory did 
not disclose the NGS methodology used.
†Sanger sequencing.
WT, wild type.
Table 5 Most commonly reported variants in each gene and clinically 
relevant mutations
Gene
Most commonly reported 
variant by participants
Clinically relevant variants known 
to be present in the sample
BRAF c.1799T>A p.(Val600Glu) c.1799T>A p.(Val600Glu)
EGFR c.2235_2249del p.(Glu746_
Ala750del)
c.2156G>C p.(Gly719Ala); 
c.2235_2249del p.(Glu746_
Ala750del); c.2573T>G p.(Leu858Arg) 
and c.2582T>A p.(Leu861Gln)
KIT c.1727T>C p.(Leu576Asn) c.1504_1509dup p.(Ala502_
Tyr503dup) and c.1727T>C p.
(Leu576Asn)
KRAS c.35G>A p.(Gly12Asp) c.35G>A p.(Gly12Asp), c.175G>A p.
(Ala59Thr) c.183A>C p.(Gln61His) and 
c.351A>C p.(Lys117Asn)
NRAS c.35G>A p.(Gly12Asp) c.35G>A p.(Gly12Asp) and 
c.182A>G p.(Gln61Arg)
PDGFRA c.1698_1712del and 
c.2525A>T p.(Asp842Val)
c.2525A>T p.(Asp842Val)
PIK3CA c.3140A>G p.(His1047Arg) c.1624G>A p.(Glu542Lys); 
c.1633G>A p.(Glu545Lys) and 
c.3140A>G p.(His1047Arg)
Fisher to independently validate the variant frequencies within 
the reference samples prior to distribution. Multiple measure-
ments were taken and an average result determined.
In terms of the correct reporting of all variants in each gene, 
only eight laboratories reported all five variants present in NRAS 
and two laboratories correctly identified all of the eight vari-
ants in BRAF. No laboratories correctly reported all the variants 
present in any of the other genes. There were in fact several 
laboratories who failed to report the presence of any variants in 
the seven most commonly reported genes and returned a wild 
type (WT) result. These are detailed in table 4.
More variants were engineered into the reference sample than 
are clinically actionable, which may account for the differences 
seen in variant reporting. The most commonly reported variant 
in each gene is shown in table 5, along with the clinically rele-
vant variants engineered into the sample.
For NRAS, 46/63 (73%) and 44/63 (69.8%) of laborato-
ries, respectively, correctly detected the two clinically relevant 
variants; c.35G>A and c.182A>G. There were four clinically 
relevant variants in KRAS (see table 5) and these were identi-
fied by 47/68 (69.1%), 25/68 (36.8%), 37/68 (54.4%) and 28/68 
(41.2%) laboratories, respectively.
The reference sample included the four most common EGFR 
mutations associated with sensitivity to EGFR receptor tyro-
sine kinase inhibitors (TKIs): c.2156G>C, c.2235_2249del, 
c.2573T>G and c.2582T>A. These were correctly reported 
by 24/59 (40.7%), 50/59 (84.7%), 26/59 (44.1%) and 22/59 
(37.3%) laboratories, respectively. Two laboratories reported 
unexpected variants, using the Ion Torrent AmpliSeq in-house 
gene panel and an Illumina MiSeq custom panel.
The c.1799T>A mutation is the most common BRAF variant 
in melanoma and colorectal tumours, and so would be expected 
to be included in testing panels. Thirty-two of the 53 labora-
tories (60.4%) correctly reported the detection of this variant. 
Surprisingly, 39.6% of laboratories failed to do so.
Exons 10 and 21 are known PIK3CA mutation hotspots, and 
3 of the 24 variants in the reference sample are contained within 
these exons (see table 5). Of the 31 laboratories reporting a 
result for PIK3CA gene variant testing, the variant were correctly 
identified by 17/31 (54.8%), 18/31 (58.1%) and 26/319 (83.9%) 
laboratories (respectively). Two laboratories, both using the 
Qiagen GeneRead Clinically Relevant Mutations panel run on 
an Illumina MiSeq NGS platform, reported unexpected variants 
in PIK3CA. These were not reported by any other laboratory.
The KIT gene variants within exons 9 and 11, including 
c.1504_1509dup and c.1727T>A were correctly identified by 
17/25 (68%) and 18/25 (72%) laboratories, respectively. Two 
laboratories reported unexpected variants using the Ion Torrent 
AmpliSeq inhouse panel and the Illumina MiSeq with the Qiagen 
GeneRead Clinically relevant mutations panel.
For PDGFRA, the most commonly reported mutation was 
c.2525A>T, which confers resistance to TKIs. This was identified 
by 14/21 (66.7%) laboratories, along with c.1698_1712del1712, 
also by 14/21 (66.7%) laboratories.
Accuracy of testing for the presence of variants
As each laboratory was required to report the percentage variant 
frequency, it was possible to calculate a mean and median result 
for each gene. For the purposes of this analysis, the reported 
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Table 6 Calculated mean and median variant frequencies, from data 
submitted by each laboratory
Gene
Validated 
mean variant 
frequency (%)
range of participant 
reported mean 
variant frequencies 
(%)
range of participant 
reported median variant 
frequencies (%)
BRAF 2.6 4.13–8.21 4.10–5.00
EGFR 2.6 3.62–8.84 4.00–7.59
KIT 4.2 7.00–17.00 5.99–17.40
KRAS 4.3 5.71–10.55 6.06–9.09
NRAS 7.4 11.85–16.16 11.43–15.74
PDGFRA 4.2 9.37–15.00 8.18–11.22
PIK3CA 4.7 10.00–17.80 9.41–17.00
Figure 2 Variant frequencies reported by participating laboratories, using NGS platforms. The bars represent the percentage variation (+/–) 
from the validated test allelic frequency. Bars are grouped and coloured by test method. Left panel, non-NGS methodologies; Right panel, NGS 
methodologies. NGS, next generation sequencing. 
frequencies have been grouped by gene, and thus a range for 
mean and median is shown (table 6). As can be clearly seen, labo-
ratories consistently overestimated the variant allele frequency, 
particularly for variants in PIK3CA, KIT and PDGFRA. BRAF 
was the most accurately reported, in terms of mean and median 
frequencies. When the test methodology was taken into account, 
less variation was observed in single-gene testing, as opposed 
to NGS platforms (figure 2), but nonetheless, there was still an 
overestimation.
dIsCussIOn
With the concept of personalised medicine expanding rapidly 
into practice and biomarker screening becoming routine on 
many laboratories, it is more important than ever that labo-
ratories reporting these results can demonstrate high quality, 
accurate validated assays. As results from biomarker screening 
often determine patient treatment, there must be a high degree 
of confidence in the assay delivery.
One way that laboratories can demonstrate this is through 
participation in an EQA scheme, such as those developed, admin-
istered and regularly provided by UK NEQAS. In addition to the 
biannual EQA samples distributed through the CRC, GIST, lung 
cancer and melanoma schemes, laboratories also received an 
educational manufactured human cell-line reference sample. A 
complete set of validated variant and corresponding frequencies 
was provided to each participating laboratory following result 
submission to UK NEQAS.
It was reassuring to see that for the most part, the most 
frequently reported variants were those with clinical relevance. 
In terms of the variants of relevance to CRC, over two-thirds of 
laboratories reported the two mutations in NRAS, and between 
36.8% and 69% correctly identified the clinically relevant vari-
ants in KRAS. The variant allele frequency of the NRAS variants 
was 7.4%, compared with 4.3% for the KRAS variants, which 
may have explained the lower level of detection for the latter 
gene variants. Furthermore, slightly more laboratories used NGS 
for the detection of NRAS mutations, compared with KRAS, 
possibly providing an overall lower limit of detection. We must 
not exclude the possibility that some laboratories do not report 
mutant allele frequencies below 5%, and thus did detect, but did 
not report the KRAS variants, which they may have found below 
their lower limit for reporting. Laboratories were encouraged to 
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review their raw data following release of the validated variant 
data.
Sixty per cent of laboratories correctly identified the common 
c.1799T>A p.(V600E) mutation in BRAF, in spite of the manu-
factured variant allele frequency being stated as 2.6%. In CRC 
screening, BRAF is likely to be included in gene panels due to 
the poor prognosis that this codon 600 mutation confers, and 
its association with microsatellite instability, both of which will 
be assessed as part of Lynch Screening (https://www. nice. org. uk/ 
guidance/ dg27). In melanoma, the presence of this mutation is 
indicative of response to anti-EGFR therapy.
The four clinically relevant variants in EGFR were identi-
fied by very differing percentages of participating laborato-
ries, ranging from 37.3% for c.2582T>A p. (Leu861Gln), up 
to 84.7% for c.2235_2249del p.(Glu746_Ala750del). This 
may again be as a result of the very low mean variant allele 
frequency (2.6%) resulting in laboratories not reporting low 
level mutations, but the clinical importance of correct muta-
tion identification should be highlighted, as patients whose 
non-small-cell lung cancers contains such mutations, will fail 
to respond to TKIs.
Mutation screening of GIST tumours is complex as these 
tumours arise as a result of a driver mutation in either KIT of 
PRGFRA. In addition, there are multiple mutation types, making 
these tumours difficult to accurately screen. Reassuringly, two 
thirds of laboratories correctly identified the activating mutation 
in exon 18 of PDGFRA, which confers resistance to TKIs, and 
again over two thirds correctly identified activating mutations in 
KIT.
Overall, the fact that clinically relevant and actionable variants 
were reported most frequently, provides reassuring evidence that 
gene tests have been optimised to detect the majority of clinical 
important variants in most laboratories.
There were several laboratories which failed to identify any 
variants in the sample and reported it as WT. With the excep-
tion of KIT gene testing, Sanger Sequencing was reported as the 
testing methodology for each gene in at least one laboratory. It 
is widely acknowledged that the limit of detection for Sanger 
Sequencing19 is 20%–25% mutant allele frequency in a WT allele 
background, which may explain the failure to detect the variants 
presence at lower levels.
Twenty-one laboratories did not detect a variant in the BRAF 
gene. There was huge variation in the testing methodologies 
used and this perhaps demonstrates reduced access to a more 
sensitive NGS-based tests for variant detection for this gene. 
KRAS was the next most common gene to be reported as WT 
(by seven laboratories). The Scheme has seen a large increase 
in laboratories participating for the first time with limited 
biomarker molecular testing experience. There is a possibility 
that such laboratories have limited access to high sensitivity 
sequencing platforms.
We cannot ignore the engineered artificial nature of the sample, 
as a contributing factor when it comes to incorrect variant detec-
tion. Samples usually received as part of the standard EQA schemes 
are also FFPE in nature, but consist of a single human tumour 
sample, rather than an engineered FFPE cell-line. Furthermore, as 
the reference sample consisted of a single tissue FFPE curl, this 
would not have been a standard sample format for many partic-
ipating laboratories and thus added in an additional variable to 
standard sample processing pipelines.
Increasingly, laboratories are being expected to obtain 
molecular test results from small and often challenging biopsy 
samples. To meet these challenges, these laboratories must 
ensure that their assay design has been fully optimised and that 
the scope of gene testing is sufficient to meet the requirements 
of the tests.
Having the ability to test samples such as this reference sample 
and receive the full genotyping results from UK NEQAS should 
provide high quality validation information and alert laborato-
ries to any suboptimal assays. This should guide reoptimisation 
to ensure high quality sample screening.
Take home messages
 ► Laboratories carrying out mutation screening must maximise 
opportunities to enrol in External Quality Assurance schemes.
 ► Provision of the complete mutation profile of the reference 
sample to laboratories has allowed, where required, assay 
optimisation procedures to be undertaken.
 ► Schemes such as those run by UK NEQAS offer samples 
for testing and educational support, which must not be 
overlooked and should be embraced.
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